Sitagliptin (Januvia™) is a new oral agent ... including T-cell activation and proliferation. Although the mechanism of action may indicate that DPP-4 inhibition is a promising treatment for ...

Janumet™ (MK-0431A) combines two OADs with complementary mechanisms of action to improve glycemic control, sitagliptin and metformin. The tablet was designed in order to be bioequivalent to ...

Both Victoza® and Januvia® were well tolerated ... Due to this glucose-dependent mechanism of action, Victoza® is associated with a low rate of hypoglycaemia. The mechanism of blood sugar ...

The popular diabetes drug Januvia may contain traces of a probable carcinogen, but patients should keep using the medication because it could be dangerous to stop taking it, the U.S. Food and Drug ...

which is marketed in the U.S. as Merck's Januvia. With their differing mechanisms of action, the combo is expected to provide greater glycemic lowering effects than either drug alone, according to ...

JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes. JANUVIA should not be used in patients with type 1 diabetes or for the ...